Washington, D.C. 20549










Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report: September 16, 2013

(Date of earliest event reported)




WhiteHorse Finance, Inc.

(Exact name of registrant as specified in its charter)




Delaware 814-00967 45-4247759

(State or other jurisdiction

of incorporation)


File Number)

(IRS Employer

Identification Number)


1450 Brickell Avenue, 31st Floor

Miami Florida

(Address of principal executive offices) (Zip Code)


(305) 379-2322

(Registrant’s telephone number, including area code)


Not Applicable

(Former Name or Former Address, if changed since last report)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 8.01. Other Events.


On September 16, 2013, Acella Pharmaceuticals, LLC (“Acella”) repaid in full WhiteHorse Finance, Inc.’s (the “Company”) investment in the first lien secured term loan to Acella due December 30, 2015. In connection with the repayment by Acella, the Company received approximately $59.7 million in principal prepayment. The Company also received a 3% pre-payment fee.






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: September 18, 2013 WHITEHORSE FINANCE, INC.  

/s/ Alastair G. C. Merrick


Alastair G. C. Merrick 

    Chief Financial Officer & Treasurer